Table 1 Demographic information and clinical characteristics of the 370 patients
Variables | Number (%) | Mean ± SD; Median (range) | P value |
|---|---|---|---|
AQP1 tumor 0 1 2 3 4 6 8 9 12 | 77 (20.92) 5 (1.36) 23 (2.73) 16 (4.35) 46 (12.5) 29 (7.88) 125 (33.97) 4 (1.09) 43 (11.68) | 5.46 ± 3.90; 6 (0–12) | |
AQP1 classification tumor | |||
Unknown | 2 (0.54) | ||
Low | 82 (22.16) | ||
High | 286 (72.43) | ||
AQP1 normal 0 1 2 3 4 6 8 9 12 | 6 (1.98) 1 (0.33) 5 (1.65) 16 (5.28) 19 (6.27) 63 (20.79) 9 (2.97) 27 (8.91) 157 (51.82) | 8.95 ± 3.56; 12 (0–12) | |
AQP1 classification normal | 0.913 | ||
Unknown | 67 (18.11) | ||
Low | 7 (18.92) | ||
High | 296 (80.00) | ||
OS censor | < 0.001* | ||
Alive | 276 (92.31) | ||
Dead Unknown | 23 (7.69) 71 (19.19) | ||
OS | 42.24 ± 9.34; 41 (7–62) | ||
OS classification (months) | 0.096 | ||
High | 161 (43.51) | ||
Low Unknown | 134 (36.21) 75 (20.27) | ||
PFS | 40.99 ± 10.95; 41 (0–62) | ||
PFS classification (months) | 0.032* | ||
High | 154 (41.62) | ||
Low Unknown | 141 (38.10) 75 (20.27) | ||
Age (category) | 56.61 ± 12.47; 55 (21–88) | 0.267 | |
21–40 | 33 (8.92) | ||
41–60 | 194 (52.43) | ||
61–88 | 143 (38.65) | ||
Gender | 0.931 | ||
Female | 114 (30.81) | ||
Male | 256 (69.19) | ||
KIRC | < 0.001* | ||
Yes | 328 (88.65) | ||
No | 41 (11.08) | ||
Histopathological classification | < 0.001* | ||
KIRC | 328 (88.65) | ||
KIRP | 18 (4.86) | ||
KICH | 8 (2.16) | ||
Others | 16 (4.32) | ||
Fuhrman nuclear stage | 0.007* | ||
Stage 1 | 69 (18.65) | ||
Stage 2 | 234 (63.24) | ||
Stage 3 | 51 (13.78) | ||
Stage 4 | 16 (4.32) | ||
T stage score | 2.12 ± 1.54; 2 (1–8) | < 0.001* | |
T stage | < 0.001* | ||
T1 | 282 (76.22) | ||
T2 | 29 (7.84) | ||
T3 | 53 (14.32) | ||
T4 Unknown | 3 (0.81) 3 (0.81) | ||
Detailed T stage | < 0.001* | ||
1a | 178 (48.11) | ||
1b | 104 (28.11) | ||
2a | 17 (4.59) | ||
2b | 12 (3.24) | ||
3a | 49 (13.24) | ||
3b | 2 (0.54) | ||
3c | 2 (0.54) | ||
4 Unknown | 3 (0.81) 3 (0.81) | ||
N stage | |||
Yes | 2 (0.54) | ||
No | 368 (11.08) | ||
M stage | |||
Yes | 0 (0.00) | ||
No | 370 (100.00) | ||
Stage | < 0.001* | ||
Stage 1 | 282 (76.22) | ||
Stage 2 | 28 (7.84) | ||
Stage 3 | 54 (14.59) | ||
Stage 4 Unknown | 3 (0.81) 3 (0.81) | ||
Progression after treatment | < 0.001* | ||
Yes | 42 (11.35) | ||
No Unknown | 257 (69.45) 71 (19.19) |